Showing results (1-10 of 345) with videos related to
Sort By:
Pageof 35
Current Opinion in Neurology|April 2, 2026
Big data in multiple sclerosisMaria Trojano, Pietro IaffaldanoNeurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 15, 2018
Natalizumab reduces serum pro-angiogenic activity in MS patientsPietro Iaffaldano, Domenico Ribatti, Maria TrojanoExpert Review of Neurotherapeutics|November 19, 2011
Treating multiple sclerosis with natalizumabPietro Iaffaldano, Guglielmo Lucchese, Maria TrojanoJournal of Neurology|June 5, 2016
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patientsPietro Iaffaldano, Rosa Gemma Viterbo, Maria TrojanoClinical and Experimental Medicine|December 26, 2014
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patientsDomenico Ribatti, Pietro Iaffaldano, Christian Marinaccio, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
Dengue fever in a multiple sclerosis patient taking OcrelizumabTommaso Guerra, Luca Bollo, Maria Trojano, et al.Current Opinion in Neurology|June 8, 2022
Interrogating large multiple sclerosis registries and databases: what information can be gained?Maria Trojano, Tomas Kalincik, Pietro Iaffaldano, et al.Brain, Behavior, and Immunity|September 3, 2013
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosisPietro Iaffaldano, Maddalena Ruggieri, Rosa Gemma Viterbo, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 7, 2021
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 yearsTommaso Guerra, Francesca Caputo, Bianca Orlando, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 4, 2008
Postmarketing evidence of disease-modifying drugs in multiple sclerosisMaria Trojano, Damiano Paolicelli, Aurora Fuiani, et al.Pageof 35